Tucker SL - Search Results

1

Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Akli S, et al. Among authors: tucker sl. Cancer Res. 2004 May 1;64(9):3198-208. doi: 10.1158/0008-5472.can-03-3672. Cancer Res. 2004. PMID: 15126360

2

Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy.

Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Bedrosian I, et al. Among authors: tucker sl. Clin Cancer Res. 2007 Aug 15;13(16):4800-6. doi: 10.1158/1078-0432.CCR-07-0142. Clin Cancer Res. 2007. PMID: 17699858

3

Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression.

Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K. Wingate H, et al. Among authors: tucker sl. Cell Cycle. 2009 Apr 1;8(7):1062-8. doi: 10.4161/cc.8.7.8119. Epub 2009 Apr 10. Cell Cycle. 2009. PMID: 19305161 Free PMC article.

4

Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.

Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Akli S, et al. Among authors: tucker sl. Clin Cancer Res. 2010 Feb 15;16(4):1179-90. doi: 10.1158/1078-0432.CCR-09-1787. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145171 Free PMC article.

5

Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer.

Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Akli S, et al. Among authors: tucker sl. Cell Cycle. 2012 Apr 1;11(7):1468-76. doi: 10.4161/cc.19882. Epub 2012 Apr 1. Cell Cycle. 2012. PMID: 22441703 Free PMC article.

6

Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.

Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Akli S, et al. Cancer Res. 2007 Aug 1;67(15):7212-22. doi: 10.1158/0008-5472.CAN-07-0599. Cancer Res. 2007. PMID: 17671189

7

Cyclin E and survival in patients with breast cancer.

Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Keyomarsi K, et al. Among authors: tucker sl. N Engl J Med. 2002 Nov 14;347(20):1566-75. doi: 10.1056/NEJMoa021153. N Engl J Med. 2002. PMID: 12432043 Free article.

8

A novel interaction between HER2/neu and cyclin E in breast cancer.

Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. Mittendorf EA, et al. Among authors: tucker sl. Oncogene. 2010 Jul 8;29(27):3896-907. doi: 10.1038/onc.2010.151. Epub 2010 May 10. Oncogene. 2010. PMID: 20453888 Free PMC article.

9

Predominance of the metastatic phenotype in somatic cell hybrids of the K-1735 murine melanoma.

Staroselsky AH, Pathak S, Chernajovsky Y, Tucker SL, Fidler IJ. Staroselsky AH, et al. Among authors: tucker sl. Cancer Res. 1991 Dec 1;51(23 Pt 1):6292-8. Cancer Res. 1991. PMID: 1834329

10

Cyclin E is a more powerful predictor of breast cancer outcome than proliferation.

Keyomarsi K, Tucker SL, Bedrosian I. Keyomarsi K, et al. Among authors: tucker sl. Nat Med. 2003 Feb;9(2):152. doi: 10.1038/nm0203-152. Nat Med. 2003. PMID: 12563321 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

278 results

Search Page